KR100625708B1 - 수용체에 결합하는 펩티드 및 화합물 - Google Patents

수용체에 결합하는 펩티드 및 화합물 Download PDF

Info

Publication number
KR100625708B1
KR100625708B1 KR1019997005169A KR19997005169A KR100625708B1 KR 100625708 B1 KR100625708 B1 KR 100625708B1 KR 1019997005169 A KR1019997005169 A KR 1019997005169A KR 19997005169 A KR19997005169 A KR 19997005169A KR 100625708 B1 KR100625708 B1 KR 100625708B1
Authority
KR
South Korea
Prior art keywords
compound
peptide
pharmaceutically acceptable
compounds
acid
Prior art date
Application number
KR1019997005169A
Other languages
English (en)
Korean (ko)
Other versions
KR20000069408A (ko
Inventor
윌리암 제이. 다우어
로날드 더블유. 배렛
스티븐 이. 퀼라
크리스찬 엠. 게이츠
피터 제이. 섀츠
팔라니아판 발라수브라마니안
크리스토퍼 알. 왁스트롬
리차드 웨인 헨드렌
랜돌프 비. 디프린스
수레카 파두투리
쿤 인
Original Assignee
글락소 그룹 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25071323&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR100625708(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 글락소 그룹 리미티드 filed Critical 글락소 그룹 리미티드
Priority to KR1020057005233A priority Critical patent/KR100668546B1/ko
Publication of KR20000069408A publication Critical patent/KR20000069408A/ko
Application granted granted Critical
Publication of KR100625708B1 publication Critical patent/KR100625708B1/ko

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/524—Thrombopoietin, i.e. C-MPL ligand
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1019997005169A 1996-12-11 1997-12-09 수용체에 결합하는 펩티드 및 화합물 KR100625708B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020057005233A KR100668546B1 (ko) 1996-12-11 1997-12-09 수용체에 결합하는 펩티드 및 화합물

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/764,640 US5869451A (en) 1995-06-07 1996-12-11 Peptides and compounds that bind to a receptor
US08/764,640 1996-12-11
US8/764,640 1996-12-11
PCT/EP1997/006850 WO1998025965A2 (en) 1996-12-11 1997-12-09 Peptides and compounds that bind to the thrombopoietin receptor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020057005233A Division KR100668546B1 (ko) 1996-12-11 1997-12-09 수용체에 결합하는 펩티드 및 화합물

Publications (2)

Publication Number Publication Date
KR20000069408A KR20000069408A (ko) 2000-11-25
KR100625708B1 true KR100625708B1 (ko) 2006-09-20

Family

ID=25071323

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020057005233A KR100668546B1 (ko) 1996-12-11 1997-12-09 수용체에 결합하는 펩티드 및 화합물
KR1019997005169A KR100625708B1 (ko) 1996-12-11 1997-12-09 수용체에 결합하는 펩티드 및 화합물
KR1020067003807A KR100679576B1 (ko) 1996-12-11 1997-12-09 수용체에 결합하는 펩티드 및 화합물

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR1020057005233A KR100668546B1 (ko) 1996-12-11 1997-12-09 수용체에 결합하는 펩티드 및 화합물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020067003807A KR100679576B1 (ko) 1996-12-11 1997-12-09 수용체에 결합하는 펩티드 및 화합물

Country Status (24)

Country Link
US (2) US5869451A (US06373033-20020416-M00071.png)
EP (3) EP2028191A1 (US06373033-20020416-M00071.png)
JP (1) JP4128225B2 (US06373033-20020416-M00071.png)
KR (3) KR100668546B1 (US06373033-20020416-M00071.png)
CN (1) CN100379760C (US06373033-20020416-M00071.png)
AR (2) AR010752A1 (US06373033-20020416-M00071.png)
AT (1) ATE420893T1 (US06373033-20020416-M00071.png)
AU (1) AU725731B2 (US06373033-20020416-M00071.png)
BR (1) BRPI9713914B1 (US06373033-20020416-M00071.png)
CA (1) CA2274149C (US06373033-20020416-M00071.png)
CO (1) CO5080768A1 (US06373033-20020416-M00071.png)
DE (1) DE69739219D1 (US06373033-20020416-M00071.png)
ES (1) ES2321038T3 (US06373033-20020416-M00071.png)
HR (1) HRP970683B1 (US06373033-20020416-M00071.png)
MA (1) MA26454A1 (US06373033-20020416-M00071.png)
PA (1) PA8442601A1 (US06373033-20020416-M00071.png)
PE (1) PE27599A1 (US06373033-20020416-M00071.png)
SV (1) SV1997000104A (US06373033-20020416-M00071.png)
TN (1) TNSN97201A1 (US06373033-20020416-M00071.png)
TR (2) TR200401638T2 (US06373033-20020416-M00071.png)
TW (1) TW515804B (US06373033-20020416-M00071.png)
UY (1) UY24805A1 (US06373033-20020416-M00071.png)
WO (1) WO1998025965A2 (US06373033-20020416-M00071.png)
ZA (1) ZA9711045B (US06373033-20020416-M00071.png)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200059213A (ko) * 2017-07-26 2020-05-28 잔센파마슈티카엔.브이. 표적화된 방사선 치료요법에 의해 유도된 혈관 무결성을 보호하는 방법

Families Citing this family (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869451A (en) * 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
WO1996040750A1 (en) * 1995-06-07 1996-12-19 Glaxo Group Limited Peptides and compounds that bind to a thrombopoietin receptor
US6251864B1 (en) 1995-06-07 2001-06-26 Glaxo Group Limited Peptides and compounds that bind to a receptor
US7091311B2 (en) 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
US7083983B2 (en) * 1996-07-05 2006-08-01 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
AU739173B2 (en) * 1997-10-31 2001-10-04 Ligand Pharmaceuticals Incorporated Novel metal complexes
ES2301215T3 (es) 1997-10-31 2008-06-16 Smithkline Beecham Corporation Complejos de metal con efectos antibacterianos y fungicidas.
JP2001521896A (ja) 1997-10-31 2001-11-13 スミスクライン・ビーチャム・コーポレイション 新規な金属錯体
US7488590B2 (en) * 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
BRPI9914698B8 (pt) 1998-10-23 2021-05-25 Amgen Inc composto que se liga a um receptor mp1, e , composição farmacêutica.
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
EP1225901A2 (en) * 1999-09-21 2002-07-31 Emory University Uses and compositions for treating platelet-related disorders using anagrelide
US7668658B2 (en) 1999-10-13 2010-02-23 Sequenom, Inc. Methods for generating databases and databases for identifying polymorphic genetic markers
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
AU784746B2 (en) 1999-11-18 2006-06-08 Dendreon Corporation Nucleic acids encoding endotheliases, endotheliases and uses thereof
TWI284639B (en) * 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
US7700341B2 (en) * 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
EP1278778A2 (en) * 2000-05-03 2003-01-29 Amgen Inc., Modified peptides, comprising an fc domain, as therapeutic agents
US20050158838A1 (en) * 2000-06-19 2005-07-21 Dyax Corp., A Delaware Corporation Novel enterokinase cleavage sequences
US7396917B2 (en) * 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US20040253242A1 (en) * 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
EP1589034B1 (en) 2000-12-05 2008-11-19 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US7125703B2 (en) 2001-03-13 2006-10-24 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
JP2004535166A (ja) 2001-03-22 2004-11-25 デンドレオン・サンディエゴ・リミテッド・ライアビリティ・カンパニー セリンプロテアーゼｃｖｓｐ１４をコードする核酸分子、コードされるポリペプチドおよびそれに基づく方法
KR20030096292A (ko) 2001-03-27 2003-12-24 덴드레온 샌 디에고 엘엘씨 트랜스막 세린 프로테아제 9를 암호화하는 핵산 분자,암호화된 폴리펩티드 및 이에 근거한 방법
US7112430B2 (en) 2001-05-14 2006-09-26 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon
US7332474B2 (en) * 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
US20030134794A1 (en) * 2001-11-20 2003-07-17 Madison Edwin L. Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
IL158569A0 (en) * 2002-06-29 2004-05-12 Aquanova Ger Solubilisate Tech Isoflavone concentrates and methods for the production thereof
US20040028661A1 (en) * 2002-08-07 2004-02-12 Bartelmez Stephen H. Expansion of cells using thrombopoietin and anti-transforming growth factor-beta
CA2495184A1 (en) 2002-08-14 2004-02-26 Nissan Chemical Industries, Ltd. Thrombopoietin receptor activators and process for their production
US8227411B2 (en) * 2002-08-20 2012-07-24 BioSurface Engineering Technologies, Incle FGF growth factor analogs
US7166574B2 (en) 2002-08-20 2007-01-23 Biosurface Engineering Technologies, Inc. Synthetic heparin-binding growth factor analogs
US7598224B2 (en) 2002-08-20 2009-10-06 Biosurface Engineering Technologies, Inc. Dual chain synthetic heparin-binding growth factor analogs
NZ566812A (en) * 2002-09-18 2009-07-31 Ortho Mcneil Pharm Inc Methods of increasing platelet and hematopoietic stem cell production
TWI324593B (en) 2002-10-09 2010-05-11 Nissan Chemical Ind Ltd Pyrazolone compounds and thrombopoietin receptor activator
US20040248798A1 (en) 2003-02-14 2004-12-09 Peter Sutovsky Contraceptive methods and compositions related to proteasomal interference
NZ563042A (en) 2003-05-12 2008-09-26 Affymax Inc Novel spacer moiety for poly(ethylene glycol)-modified peptide-based compounds
AU2004238869B2 (en) * 2003-05-12 2009-06-25 Affymax, Inc. Novel poly(ethylene glycol) modified compounds and uses thereof
SG160224A1 (en) * 2003-05-12 2010-04-29 Affymax Inc Novel peptides that bind to the erythropoietin receptor
KR101227666B1 (ko) * 2003-05-12 2013-01-31 아피맥스, 인크. 에리스로포이에틴 수용체에 결합하는 펩티드
KR100776961B1 (ko) * 2003-08-12 2007-11-28 시오노기세이야쿠가부시키가이샤 트롬보포이에틴 수용체 아고니스트 작용을 가지는 화합물
ES2626107T3 (es) * 2003-08-28 2017-07-24 Janssen Pharmaceuticals, Inc. Péptidos y compuestos que se unen al receptor de trombopoyetina
US7723295B2 (en) * 2003-08-28 2010-05-25 Ortho-Mcneil Pharmaceutical, Inc. Peptides and compounds that bind to a receptor
EP1701969B1 (en) 2003-12-31 2007-10-24 F.Hoffmann-La Roche Ag Process for peptide synthesis using a reduced amount of deprotection agent
US7414028B1 (en) 2004-02-04 2008-08-19 Biosurface Engineering Technologies, Inc. Growth factor analogs
US7528105B1 (en) 2004-02-10 2009-05-05 Biosurface Engineering Technologies Heterodimeric chain synthetic heparin-binding growth factor analogs
US20080227696A1 (en) * 2005-02-22 2008-09-18 Biosurface Engineering Technologies, Inc. Single branch heparin-binding growth factor analogs
US20060024347A1 (en) * 2004-02-10 2006-02-02 Biosurface Engineering Technologies, Inc. Bioactive peptide coatings
US7671012B2 (en) 2004-02-10 2010-03-02 Biosurface Engineering Technologies, Inc. Formulations and methods for delivery of growth factor analogs
CA2555583A1 (en) * 2004-02-20 2005-09-09 Biosurface Engineering Technologies, Inc. Positive modulator of bone morphogenic protein-2
US8143380B2 (en) * 2004-07-08 2012-03-27 Amgen Inc. Therapeutic peptides
US20060210542A1 (en) * 2004-08-16 2006-09-21 Yurkow Edward J Use of TPO mimetic compounds and pharmaceutical compositions in the treatment of anemia
EP1797127B1 (en) 2004-09-24 2017-06-14 Amgen Inc. Modified fc molecules
US7589063B2 (en) 2004-12-14 2009-09-15 Aplagen Gmbh Molecules which promote hematopoiesis
CN101142234A (zh) * 2004-11-11 2008-03-12 阿费麦克斯公司 结合红细胞生成素受体的新肽
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
RU2395505C2 (ru) 2004-12-08 2010-07-27 Ниссан Кемикал Индастриз, ЛТД 3-этилиденгидразино-замещенные гетероциклические соединения в качестве активаторов рецептора тромбопоэтина
TWI399368B (zh) 2004-12-14 2013-06-21 Nissan Chemical Ind Ltd Amide compounds and thrombopoietin receptor activators
US8258258B2 (en) 2005-03-10 2012-09-04 Biontech Ag Dimeric or multimeric microproteins
WO2006094530A1 (en) * 2005-03-11 2006-09-14 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
EP1907417A2 (en) * 2005-06-23 2008-04-09 AplaGen GmbH Supravalent compounds
JP5071375B2 (ja) 2005-07-15 2012-11-14 日産化学工業株式会社 チオフェン化合物及びトロンボポエチンレセプター活性化剤
EP1904488B1 (en) 2005-07-20 2013-03-06 Nissan Chemical Industries, Ltd. Pyrazole compounds and thrombopoietin receptor activators
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
JP5205967B2 (ja) 2005-11-07 2013-06-05 日産化学工業株式会社 ヒドラジド化合物及びトロンボポエチンレセプター活性化剤
WO2007102946A2 (en) 2006-01-23 2007-09-13 Amgen Inc. Crystalline polypeptides
US7879318B2 (en) 2006-01-23 2011-02-01 Mcw Research Foundation, Inc. Method of reducing the effects of ischemia by administration of a thrombopoietin receptor ligand
EP1986677A2 (en) * 2006-01-25 2008-11-05 Amgen Inc. Thrombopoietic compounds
EP1834963A1 (en) * 2006-03-13 2007-09-19 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
ATE485517T1 (de) * 2006-03-22 2010-11-15 Viral Logic Systems Technology Verfahren zur identifizierung von polypeptid- targets
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
US8377448B2 (en) * 2006-05-15 2013-02-19 The Board Of Trustees Of The Leland Standford Junior University CD47 related compositions and methods for treating immunological diseases and disorders
US20080131431A1 (en) * 2006-05-15 2008-06-05 Viral Logic Systems Technology Corp. CD47 related compositions and methods for treating immunological diseases and disorders
US7820172B1 (en) 2006-06-01 2010-10-26 Biosurface Engineering Technologies, Inc. Laminin-derived multi-domain peptides
WO2007142308A1 (ja) 2006-06-07 2007-12-13 Nissan Chemical Industries, Ltd. 含窒素ヘテロ環化合物及びトロンボポエチンレセプター活性化剤
US7981425B2 (en) * 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
CA2692240C (en) * 2006-06-22 2018-03-13 Biosurface Engineering Technologies, Inc. Composition and method for delivery of bmp-2 amplifier/co-activator for enhancement of osteogenesis
WO2008051383A2 (en) * 2006-10-19 2008-05-02 Amgen Inc. Use of alcohol co-solvents to improve pegylation reaction yields
EP2118127A4 (en) * 2007-01-31 2010-12-01 Affymax Inc NICKET-BASED LINKER FOR BONDING MODIFYING GROUPS OF POLYPEPTIDES AND OTHER MACROMOLECULES
CA2687141C (en) 2007-05-22 2014-04-01 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
WO2008157824A2 (en) * 2007-06-21 2008-12-24 Conjuchem Biotechnologies Inc. Thrombopoietin peptide conjugates
WO2009029682A1 (en) * 2007-08-28 2009-03-05 Rigel Pharmaceuticals, Inc. Combination therapy with syk kinase inhibitor
US8183342B2 (en) * 2007-11-06 2012-05-22 Case Western Reserve University Method of treating chemotherapy-induced thrombocytopenia
CN101481352A (zh) 2008-01-10 2009-07-15 上海恒瑞医药有限公司 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用
JP5701064B2 (ja) 2008-01-25 2015-04-15 アムジエン・インコーポレーテツド フェロポーチン抗体およびその使用方法
WO2009139822A1 (en) 2008-05-01 2009-11-19 Amgen Inc. Anti-hepcidin antibodies and methods of use
US20120121591A1 (en) 2009-03-20 2012-05-17 Amgen Inc. SELECTIVE AND POTENT PEPTIDE INHIBITORS OF Kv1.3
WO2011012306A2 (en) 2009-07-30 2011-02-03 Aplagen Gmbh Use of emps for antagonising epo-stimulatory effects on epo-responsive tumors while maintaining erythropoiesis
US8889732B2 (en) 2009-10-23 2014-11-18 Nissan Chemical Industries, Ltd. Fused heterocyclic compounds and thrombopoietin receptor activators
WO2011098095A1 (en) 2010-02-09 2011-08-18 Aplagen Gmbh Peptides binding the tpo receptor
CA2885176C (en) 2010-09-22 2018-10-23 Amgen Inc. Carrier immunoglobulins and uses thereof
WO2014159242A1 (en) 2013-03-14 2014-10-02 Novartis Ag Notch 3 mutants and uses thereof
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
SG11201701896RA (en) 2014-09-11 2017-04-27 Bristol Myers Squibb Co Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-li protein/protein interactions
US9732119B2 (en) 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
RU2758608C2 (ru) 2014-11-19 2021-11-01 Конинклейке Филипс Н.В. Способ диагностики с использованием hnl
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
DK3458111T3 (da) 2016-05-19 2021-04-26 Bristol Myers Squibb Co Immunomodulatorer til pet-billeddannelse
US10988507B2 (en) 2016-11-07 2021-04-27 Bristol-Myers Squibb Company Immunomodulators
CN110997698B (zh) 2017-06-23 2023-12-26 百时美施贵宝公司 充当pd-1拮抗剂的免疫调节剂
KR20200058506A (ko) 2017-10-03 2020-05-27 브리스톨-마이어스 스큅 컴퍼니 면역조정제
JP2022523295A (ja) 2019-01-25 2022-04-22 ヤンセン ファーマシューティカ エヌ．ベー． 発疱剤および苛性ガスの毒性作用を緩和する方法
AU2020211412A1 (en) * 2019-01-25 2021-08-12 Janssen Pharmaceutica Nv Methods for mitigating liver injury and promoting liver hypertrophy, regeneration and cell engraftment in conjunction with radiation and/or radiomimetic treatments
CN113660943A (zh) 2019-01-25 2021-11-16 詹森药业有限公司 增强对全身放射/化学暴露反应的对器官和血管损伤的保护、造血恢复以及存活的方法
WO2023056444A1 (en) 2021-10-01 2023-04-06 Janssen Pharmaceutica N.V. Methods of increasing progenitor cell production
WO2024095178A1 (en) 2022-11-01 2024-05-10 Janssen Pharmaceutica Nv Thrombopoietin mimetic for use in the treatment of acute liver failure

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2046920B1 (US06373033-20020416-M00071.png) 1969-06-19 1974-05-03 Citizen Watch Co Ltd
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4612132A (en) 1984-07-20 1986-09-16 Chevron Research Company Modified succinimides
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5198424A (en) * 1989-03-08 1993-03-30 Board Of Regents Of The University Of Oklahoma Functionally active selectin-derived peptides
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5326558A (en) * 1989-08-08 1994-07-05 Genetics Institute, Inc. Megakaryocytopoietic factor
IL96477A0 (en) * 1989-12-01 1991-08-16 Amgen Inc Megakaryocyte production
US5571508A (en) * 1989-12-18 1996-11-05 Amrad Corporation Limited Method for the treatment of thrombocytopenia and pharmaceutical compositions useful therefor
IT1241395B (it) * 1990-04-02 1994-01-10 Eniricerche Spa Composti immunogenici,il procedimento per la loro sintesi e loro impiego per la preparazione di vaccini antimalaria
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5250732A (en) * 1991-07-18 1993-10-05 Genentech, Inc. Ketamine analogues for treatment of thrombocytopenia
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
PT644771E (pt) * 1992-06-11 2002-12-31 Alkermes Inc Sistema de entrega da droga eritropoietina
US5354934A (en) 1993-02-04 1994-10-11 Amgen Inc. Pulmonary administration of erythropoietin
AU685506B2 (en) 1993-08-25 1998-01-22 Systemix, Inc. Method for producing a highly enriched population of hematopoietic stem cells
AU8124694A (en) * 1993-10-29 1995-05-22 Affymax Technologies N.V. In vitro peptide and antibody display libraries
SG47030A1 (en) * 1994-01-03 1998-03-20 Genentech Inc Thrombopoietin
WO1995021626A1 (en) * 1994-02-14 1995-08-17 University Of Washington Methods for stimulating erythropoiesis using thrombopoietin
WO1995021920A1 (en) * 1994-02-14 1995-08-17 Zymogenetics, Inc. Hematopoietic protein and materials and methods for making it
SG79882A1 (en) * 1994-02-14 2001-04-17 Kirin Brewery Protein having tpo activity
WO1995021919A2 (en) * 1994-02-14 1995-08-17 Kirin Brewery Company, Limited Protein having tpo activity
ATE169335T1 (de) * 1994-03-31 1998-08-15 Amgen Inc Zusammensetzungen und verfahren zur anregung des wachstums und der differenzierung von megakaryozyten
US5571686A (en) * 1994-04-14 1996-11-05 Massachusetts Institute Of Technology Method of using megapoietin for prolonging the survival & viability of platlets
US5641655A (en) * 1994-11-30 1997-06-24 Zymogenetics, Inc. Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide
WO1996017062A1 (en) * 1994-11-30 1996-06-06 Zymogenetics, Inc. Low molecular weight thrombopoietin
JP3763846B2 (ja) * 1995-04-26 2006-04-05 協和醗酵工業株式会社 新規ポリペプチド
US5869451A (en) * 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
WO1996040750A1 (en) * 1995-06-07 1996-12-19 Glaxo Group Limited Peptides and compounds that bind to a thrombopoietin receptor
KR102127408B1 (ko) 2014-01-29 2020-06-29 삼성전자주식회사 항 Her3 scFv 단편 및 이를 포함하는 항 c-Met/항 Her3 이중 특이 항체

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200059213A (ko) * 2017-07-26 2020-05-28 잔센파마슈티카엔.브이. 표적화된 방사선 치료요법에 의해 유도된 혈관 무결성을 보호하는 방법
KR102688415B1 (ko) * 2017-07-26 2024-07-24 잔센파마슈티카엔.브이. 표적화된 방사선 치료요법에 의해 유도된 혈관 무결성을 보호하는 조성물

Also Published As

Publication number Publication date
TR200401638T2 (tr) 2004-11-22
US5869451A (en) 1999-02-09
ATE420893T1 (de) 2009-01-15
TR199901971T2 (xx) 1999-12-21
US6121238A (en) 2000-09-19
ZA9711045B (en) 1999-06-09
KR100668546B1 (ko) 2007-01-16
KR20050042505A (ko) 2005-05-09
CA2274149A1 (en) 1998-06-18
HRP970683B1 (en) 2002-10-31
EP2028191A1 (en) 2009-02-25
PA8442601A1 (es) 2000-05-24
BRPI9713914B1 (pt) 2017-06-20
CA2274149C (en) 2008-07-15
WO1998025965A2 (en) 1998-06-18
HRP970683A2 (en) 1998-10-31
AR010752A1 (es) 2000-07-12
AR062931A2 (es) 2008-12-17
AU725731B2 (en) 2000-10-19
WO1998025965A3 (en) 1998-08-13
UY24805A1 (es) 2000-12-29
BR9713914A (pt) 2000-02-29
BRPI9713914B8 (US06373033-20020416-M00071.png) 2021-05-25
JP2001505898A (ja) 2001-05-08
CO5080768A1 (es) 2001-09-25
DE69739219D1 (de) 2009-03-05
CN100379760C (zh) 2008-04-09
PE27599A1 (es) 1999-03-29
KR20000069408A (ko) 2000-11-25
MA26454A1 (fr) 2004-12-20
AU5854798A (en) 1998-07-03
TNSN97201A1 (fr) 2005-03-15
ES2321038T3 (es) 2009-06-01
EP0948539A2 (en) 1999-10-13
SV1997000104A (es) 1998-09-18
CN1245504A (zh) 2000-02-23
KR20060025611A (ko) 2006-03-21
JP4128225B2 (ja) 2008-07-30
EP0948539B1 (en) 2009-01-14
TW515804B (en) 2003-01-01
EP2336165A1 (en) 2011-06-22
KR100679576B1 (ko) 2007-02-07

Similar Documents

Publication Publication Date Title
KR100625708B1 (ko) 수용체에 결합하는 펩티드 및 화합물
US6251864B1 (en) Peptides and compounds that bind to a receptor
JP4949844B2 (ja) エリスロポエチン受容体に結合する新規ペプチド
JP6426107B2 (ja) Ａｐｊ受容体アゴニストおよびその使用
ZA200602495B (en) Peptides and compounds that bind to thrombopoietin receptors
KR20090005300A (ko) 펩티드 및 펩티드 유도체와 이들을 함유하는 약학적 조성물
JP2009504650A (ja) Ｔｐｏ受容体と結合するペプチドの使用
CN111183146A (zh) 高亲和力选择性结合cxcr4的缀合物及其使用方法
JP2008543304A (ja) ヒト顆粒球コロニー刺激因子イソ型（ＨｕｍａｎＧｒａｎｕｌｏｃｙｔｅ−ＣｏｌｏｎｙＳｔｉｍｕｌａｔｉｎｇＦａｃｔｏｒＩｓｏｆｏｒｍｓ）
MXPA99005365A (en) Peptides and compounds that bind to a receptor
CA2621857A1 (en) Peptides and compounds that bind to a receptor

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
A107 Divisional application of patent
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120821

Year of fee payment: 7

FPAY Annual fee payment

Payment date: 20130819

Year of fee payment: 8

FPAY Annual fee payment

Payment date: 20140826

Year of fee payment: 9

FPAY Annual fee payment

Payment date: 20150819

Year of fee payment: 10

FPAY Annual fee payment

Payment date: 20160818

Year of fee payment: 11

FPAY Annual fee payment

Payment date: 20170818

Year of fee payment: 12

EXPY Expiration of term